An issue of Endo International PLC (NASDAQ:ENDP) (TSE:ENL) bonds fell 1% as a percentage of their face value during trading on Thursday. The debt issue has a 6% coupon and will mature on July 15, 2023. The debt is now trading at $77.75 and was trading at $78.88 last week. Price changes in a company’s bonds in credit markets often anticipate parallel changes in its share price.
ENDP has been the subject of a number of research analyst reports. Svb Leerink lowered shares of Endo International from an “outperform” rating to a “market perform” rating in a research note on Tuesday, March 5th. Zacks Investment Research lowered shares of Endo International from a “hold” rating to a “sell” rating in a research note on Thursday, February 7th. ValuEngine upgraded shares of Endo International from a “sell” rating to a “hold” rating in a research note on Monday, February 4th. Piper Jaffray Companies restated a “hold” rating on shares of Endo International in a research note on Friday, March 1st. Finally, TheStreet lowered shares of Endo International from a “c-” rating to a “d+” rating in a research note on Tuesday, November 27th. Fourteen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $15.44.
NASDAQ ENDP traded up $0.03 on Thursday, reaching $8.76. The company’s stock had a trading volume of 3,035,529 shares, compared to its average volume of 3,388,077. Endo International PLC has a twelve month low of $5.27 and a twelve month high of $18.50. The company has a market capitalization of $1.97 billion, a price-to-earnings ratio of 3.03 and a beta of 1.21.
Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Thursday, February 28th. The company reported $0.75 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.59 by $0.16. Endo International had a negative net margin of 35.00% and a negative return on equity of 337.13%. During the same period in the prior year, the business posted $0.77 earnings per share. On average, sell-side analysts anticipate that Endo International PLC will post 2.17 EPS for the current year.
A number of hedge funds and other institutional investors have recently bought and sold shares of ENDP. Norges Bank acquired a new stake in Endo International during the 4th quarter worth about $21,218,000. Panagora Asset Management Inc. raised its holdings in Endo International by 10,718.5% during the 3rd quarter. Panagora Asset Management Inc. now owns 1,775,205 shares of the company’s stock worth $29,877,000 after buying an additional 1,758,796 shares during the period. Teachers Advisors LLC raised its holdings in Endo International by 230.1% during the 3rd quarter. Teachers Advisors LLC now owns 1,468,025 shares of the company’s stock worth $24,707,000 after buying an additional 1,023,350 shares during the period. Canada Pension Plan Investment Board raised its holdings in Endo International by 143,723.6% during the 4th quarter. Canada Pension Plan Investment Board now owns 730,624 shares of the company’s stock worth $5,333,000 after buying an additional 730,116 shares during the period. Finally, Oregon Public Employees Retirement Fund acquired a new stake in Endo International during the 4th quarter worth about $76,000. Hedge funds and other institutional investors own 92.40% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Endo International (ENDP) Debt Trading 1% Lower” was published by Zolmax and is the property of of Zolmax. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://zolmax.com/investing/endo-international-endp-debt-trading-1-lower/2980664.html.
About Endo International (NASDAQ:ENDP)
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Read More: How do investors use RSI to grade stocks?
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.